Immunome Inc at JPMorgan Healthcare Conference Transcript
Good morning. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. On stage, we have Immunome. I will now pass the mic to their CEO, Clay Siegall, for a short presentation followed by a live audience Q&A.
Clay, welcome. The stage is yours.
Thanks, Brian, for the introduction. I am delighted to be here and thanks for JP Morgan for the invitation.
So I'm delighted to tell you a little bit about what we're doing at IO.
And Before I get going, I'd like to mention that I will be making forward-looking statements, so please refer to our SEC filings for more information.
So, at Immunome, we're working very hard on targeted oncology therapy and we're, delighted with the progress we're making. We have a passion for treating patients, and, you'll hear about that through the presentation.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
